🚀 VC round data is live in beta, check it out!
Solventum Valuation Multiples
Discover revenue and EBITDA valuation multiples for Solventum and similar public comparables like Globus Medical, Fresenius Medical Care, Medpace, Penumbra and more.
Solventum Overview
About Solventum
In spring 2024, 3M spun out its legacy healthcare segment as a stand-alone firm, Solventum. At that time, the firm comprised four segments. The smallest one—purification and filtration—has since been sold. Now, medsurg is the largest business, contributing roughly 64% of consolidated revenue, and includes advanced wound care and wound prevention. Dental solutions (restorative composites and orthodontia) and health information systems (mainly revenue cycle management) each contribute 18% of total revenue.
Founded
2023
HQ
Employees
22.0K
Website
Financials (LTM)
EV
$16B
Solventum Financials
Solventum reported last 12-month revenue of $8B and EBITDA of $2B.
In the same LTM period, Solventum generated $5B in gross profit, $2B in EBITDA, and $1B in net income.
Revenue (LTM)
Solventum P&L
In the most recent fiscal year, Solventum reported revenue of $8B and EBITDA of $3B.
Solventum expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $8B | XXX | $8B | XXX | XXX | XXX |
| Gross Profit | $5B | XXX | $4B | XXX | XXX | XXX |
| Gross Margin | 55% | XXX | 54% | XXX | XXX | XXX |
| EBITDA | $2B | XXX | $3B | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 31% | XXX | XXX | XXX |
| EBIT Margin | 21% | XXX | 21% | XXX | XXX | XXX |
| Net Profit | $1B | XXX | $2B | XXX | XXX | XXX |
| Net Margin | 13% | XXX | 19% | XXX | XXX | XXX |
| Net Debt | — | — | $4B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Solventum Stock Performance
Solventum has current market cap of $13B, and enterprise value of $16B.
Market Cap Evolution
Solventum's stock price is $73.00.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $16B | $13B | 0.0% | XXX | XXX | XXX | $8.97 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSolventum Valuation Multiples
Solventum trades at 1.9x EV/Revenue multiple, and 7.3x EV/EBITDA.
EV / Revenue (LTM)
Solventum Financial Valuation Multiples
As of March 19, 2026, Solventum has market cap of $13B and EV of $16B.
Equity research analysts estimate Solventum's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Solventum has a P/E ratio of 11.7x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $13B | XXX | $13B | XXX | XXX | XXX |
| EV (current) | $16B | XXX | $16B | XXX | XXX | XXX |
| EV/Revenue | 1.9x | XXX | 1.9x | XXX | XXX | XXX |
| EV/EBITDA | 7.3x | XXX | 6.3x | XXX | XXX | XXX |
| EV/EBIT | 9.5x | XXX | 9.5x | XXX | XXX | XXX |
| EV/Gross Profit | 3.6x | XXX | 3.6x | XXX | XXX | XXX |
| P/E | 11.7x | XXX | 8.1x | XXX | XXX | XXX |
| EV/FCF | 244.9x | XXX | (1615.7x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Solventum Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Solventum Margins & Growth Rates
Solventum's revenue in the last 12 month declined by (1%).
Solventum's revenue per employee in the last FY averaged $0.4M.
Solventum's rule of 40 is 26% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Solventum's rule of X is 24% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Solventum Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (1%) | XXX | (2%) | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 31% | XXX | XXX | XXX |
| EBITDA Growth | 2% | XXX | (14%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 26% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 24% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 7% | XXX | 9% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 46% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Solventum Public Comps
See public comps and valuation multiples for other Health Data & Analytics and Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Globus Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| Fresenius Medical Care | XXX | XXX | XXX | XXX | XXX | XXX |
| Medpace | XXX | XXX | XXX | XXX | XXX | XXX |
| Penumbra | XXX | XXX | XXX | XXX | XXX | XXX |
| Align Technology | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Solventum M&A Activity
Solventum acquired XXX companies to date.
Last acquisition by Solventum was on XXXXXXXX, XXXXX. Solventum acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Solventum
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSolventum Investment Activity
Solventum invested in XXX companies to date.
Solventum made its latest investment on XXXXXXXX, XXXXX. Solventum invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Solventum
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Solventum
| When was Solventum founded? | Solventum was founded in 2023. |
| Where is Solventum headquartered? | Solventum is headquartered in United States. |
| How many employees does Solventum have? | As of today, Solventum has over 22K employees. |
| Who is the CEO of Solventum? | Solventum's CEO is Bryan C. Hanson. |
| Is Solventum publicly listed? | Yes, Solventum is a public company listed on NYSE. |
| What is the stock symbol of Solventum? | Solventum trades under SOLV ticker. |
| When did Solventum go public? | Solventum went public in 2024. |
| Who are competitors of Solventum? | Solventum main competitors are Globus Medical, Fresenius Medical Care, Medpace, Penumbra. |
| What is the current market cap of Solventum? | Solventum's current market cap is $13B. |
| What is the current revenue of Solventum? | Solventum's last 12 months revenue is $8B. |
| What is the current revenue growth of Solventum? | Solventum revenue growth (NTM/LTM) is (1%). |
| What is the current EV/Revenue multiple of Solventum? | Current revenue multiple of Solventum is 1.9x. |
| Is Solventum profitable? | Yes, Solventum is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Solventum? | Solventum's last 12 months EBITDA is $2B. |
| What is Solventum's EBITDA margin? | Solventum's last 12 months EBITDA margin is 27%. |
| What is the current EV/EBITDA multiple of Solventum? | Current EBITDA multiple of Solventum is 7.3x. |
| What is the current FCF of Solventum? | Solventum's last 12 months FCF is $66M. |
| What is Solventum's FCF margin? | Solventum's last 12 months FCF margin is 1%. |
| What is the current EV/FCF multiple of Solventum? | Current FCF multiple of Solventum is 244.9x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.